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Aim To identify the involvement of Secreted Frizzled Related 
Protein 1 (SFRP1) promoter hypermethylation in different 
malignancy grades of astrocytoma and assess its associa-
tion with beta-catenin, lymphoid-enhancer factor 1, and 
T-cell factor 1.
Methods Twenty-six astrocytoma samples were collected 
from 2008-2015. Promoter hypermethylation was evaluat-
ed by methylation-specific polymerase-chain-reaction and 
protein expression by immunohistochemistry and stereo-
logical analysis. The staining intensity was scored by com-
paring immunoreactivity with normal tissue and by using 
10% and 50% cut-offs.
Results SFRP1 promoter methylation was found in 32% of 
astrocytomas. The number of hypermethylated samples 
increased in higher astrocytoma grades and was the high-
est in glioblastoma (P = 0.042 compared to other astrocy-
toma grades). There was 45.8% of samples with the lack of 
or weak expression of SFRP1 protein and 29.2% with strong 
expression. Samples with methylated promoter expressed 
significantly less SFRP1 than samples with unmethylated 
promoter (P = 0.031). Beta-catenin expression levels were 
elevated. Yet, glioblastomas with unmethylated SFRP1 pro-
moter had significantly less beta-catenin (P = 0.033). Strong 
expression of lymphoid-enhancer factor 1 was associated 
to higher astrocytoma grades (P = 0.006).
Conclusion SFRP1 gene was epigenetically silenced in 
glioblastomas when compared to low astrocytoma grades, 
which may suggest that the lack of its protein is involved in 
astrocytoma progression.
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Astrocytomas are the most common primary brain tu-
mors. According to the World Health Organization (WHO), 
they are classified into four malignancy grades on the ba-
sis of their histology and prognosis (1,2). The most aggres-
sive and highly malignant tumor is glioblastoma multi-
forme (GBM), a grade IV astrocytoma, with survival shorter 
than a year. For this molecularly very complex and hetero-
genic tumor, effective therapy is still missing. While pilo-
cytic astrocytomas (grade I) are considered benign, diffuse 
and anaplastic astrocytomas (grades II and III) can prog-
ress to secondary GBM, probably because of incomplete 
neurosurgical resection. Histological examination cannot 
precisely predict how these variable tumors will behave 
clinically or how fast the recurrence will occur (3-5). Since 
histologically similar tumors may differ in their molecu-
lar phenotypes, the classification of brain tumors has re-
cently included genetic profile as an additional criterion 
(2,6). Therefore, mutation of the isocitrate dehydrogenase 
1 (IDH1) gene, named R132H, present in diffuse astrocyto-
ma became an important element for the new WHO clas-
sification (7,8).
Wnt signaling pathway functions in embryonic develop-
ment and maintains adult tissue homeostasis (9,10). How-
ever, this pathway is also one of the key oncogenic path-
ways in human malignancies (11,12). It is associated with 
many human cancers and is implicated in gliomagenesis 
(13-22). Wnt signaling is usually malfunctioned by prevent-
ing beta-catenin’s degradation in the destruction complex, 
which elevates its cytosolic levels. The molecule is then 
transferred to the nucleus, where it binds to its transcrip-
tion partners – lymphoid-enhancer factor/T-cell factor 
(LEF/TCF). This molecular interaction transcriptionally stim-
ulates a number of promoters of target genes involved in 
oncogenic transformation (23).
An important regulatory role in Wnt signaling is played by 
Secreted Frizzled Related Protein (SFRP) family of genes, 
which codes for proteins that usually limit the pathway’s ac-
tivity (24-27). The suppression of the Wnt signaling by SFRP 
gene family contributes to normal development of astro-
cytes (28,29). Another mechanism involved in astrocytic tu-
morigenesis is disrupted epigenetic regulation, resulting in 
the silencing of a great variety of genes (30). A common 
mechanism for the transcriptional silencing of tumor sup-
pressor genes is promoter hypermethylation (31). SFRP1 
promoter hypermethylation and the loss of SFRP1 protein 
expression have been reported in tumorigenesis of many 
human cancers, but their involvement in astrocytoma 
progression still needs to be elucidated (1,32-34).
We believe that SFRP1 plays an important role in astrocyt-
ic brain tumors and that its expression levels, regulated by 
methylation mechanisms, change according to malignancy 
grades. Also, we hypothesized that SFRP1 expression would 
affect Wnt signaling activity. The aim of this study was to 
identify the status of SFRP1 promoter hypermethylation in 
different malignancy grades of astrocytoma in order to bet-
ter understand the molecular features and offer potential 
biomarkers. We also assessed the association of its expression 
levels with beta-catenin, TCF1, LEF1, and demographic data.
MAteriALs ANd Methods
Astrocytoma samples
Twenty-six astrocytoma samples were collected from the 
Departments of Neurosurgery and Pathology of the Univer-
sity Hospital Center (UHC) Zagreb and UHC Sestre Milosrd-
nice, Croatia from 2008-2015. The tumors were identified by 
magnetic resonance imaging in different cerebral regions. 
The patients had no family history of brain tumors or familial 
tumor syndromes, and the diagnosis was made by a board-
certified neuropathologist and classified according to WHO 
guidelines (2). There were 6 diffuse astrocytomas with WHO 
grade II (AII; 5 male and 1 female patients), 6 anaplastic as-
trocytomas with WHO grade III (AIII; 4 male and 2 female 
patients), and 14 glioblastomas with WHO grade IV (GBM; 
6 male and 8 female patients). The tumors were newly diag-
nosed, and patients did not receive any treatment prior to 
surgical resection. Our group of glioblastoma patients was 
also tested for the presence of IDH1-R132H (monoclonal an-
tibody Dianova IDH1-R132H Clone H09, Dianova, Hamburg, 
Germany) and ATRX Chromatin Remodeler (ATRX) mutations 
(polyclonal antibodies Sigma HPA001906, Sigma, Taufkirch-
en, Germany). Fifteen patients were male and 11 were fe-
male. Patient age ranged from 24 to 77 years (mean 51.9 
years; median 54.5 years). Ethical approval was received from 
the Ethics Committees of the Medical School University of 
Zagreb (Case number: 380-59-10106-14-55/147; class: 641-
01/14-02/01, July 1, 2014), University Hospital Center Sestre 
Milosrdnice (number: EP-7426/14-9, June 11, 2014), and Uni-
versity Hospital Center Zagreb (number: 02/21/JG, class: 8.1.-
14/54-2, June 23, 2014). The patients signed the informed 
consent for research participation and data presentation. 
The reference tissue was autologous normal blood DNA.
dNA extraction
Collected tumor tissues were frozen in liquid nitrogen and 
kept at -80°C. Peripheral blood samples were collected in 
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EDTA and immediately processed. Approximately 0.5 g of 
tumor tissue was homogenized with 1 mL extraction buf-
fer (10 mM TrisHCl; 0.1 M EDTA; 0.5% sodium dodecyl sul-
fate, pH 8.0) and incubated with 100 mg/mL proteinase K 
(Sigma-Aldrich, St. Louis, MI, USA) overnight at 37°C. Phe-
nol/chloroform extraction and ethanol precipitation fol-
lowed (35). Blood was used to extract leukocyte DNA; 5 mL 
of blood was lysed with 15 mL of RCLB (red blood cells lysis 
buffer; 155 mM NH4Cl; 0.1 mM EDTA; 12 mM NaHCO3) and 
centrifuged (15 min/5000 × g) at 4°C. The pellet was further 
processed in the same way as for DNA extraction from the 
tissue samples.
Methylation-specific polymerase chain reaction analysis
DNA isolated from glioblastomas (14 samples), grade II astro-
cytomas (6 samples), and grade III astrocytomas (6 samples) 
was treated with bisulfite using MethylEdge Bisulfite Con-
version System (Promega, Madison, WI, USA) according to 
manufacturer’s instructions. Bisulfite-treated DNA was used 
for methylation-specific polymerase chain reaction (MSP). 
Primer sequences for MSP of the SFRP1 promoter region 
were synthesized according to Guo et al (36): methylated 
primers, F:5’TGTAGTTTTCGGAGTTAGTGTCGCGC3’ and R:5’
CCTACGATCGAAAACGACGCGAACG3’; unmethylated prim-
ers, F:5’GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT3’ and R:5’C
TCAACCTACAATCAAAAACAACACAAACA3’. All polymerase 
chain reactions (PCRs) were performed using TaKaRa EpiTaq 
HS (for bisulfite-treated DNA, TaKaRa Bio, Mountain View, 
CA, USA): 1XEpiTaq PCR Buffer (Mg2+ free), 2.5 mM MgCl2, 0.3 
mM dNTPs, 20 pmol of each primer (Sigma-Aldrich), 50 ng 
of DNA, and 1.5 U of TaKaRa EpiTaq HS DNA Polymerase in a 
50 µL final reaction volume. PCR cycling conditions were as 
follows: initial denaturation at 95°C for 30 sec, followed by 35 
cycles consisting of 95°C for 30 sec, the respective anneal-
ing temperatures for 30 sec, and 72°C for 30 sec, followed 
by a final extension at 72°C for 7 min. Methylated SFRP1 pro-
moter region was amplified at the annealing temperature of 
65.5°C, while unmethylated region was amplified at 63.1°C. 
PCR products were separated and visualized on 2% agarose 
gels stained with GelStar (Lonza Rockland, Inc. Rockland, ME, 
USA). Positive control for methylated reaction was Methy-
lated Human Control (Promega) and that for unmethylated 
reaction were human white blood cell DNA and ovary. Neg-
ative control was nuclease-free water.
immunohistochemistry
The samples were fixed in formalin, embedded in paraffin, 
sliced into 4-μm thick sections, and mounted into capillary 
gap microscope slides (DakoCytomation, Glostrup, Den-
mark). Sections were immunostained using streptavidin 
horseradish peroxidase/DAB (Dako REAL EnVision Detection 
System Peroxidase/DAB+, Rabbit/Mouse, Dako) as described 
previously (37). The primary antibodies used were as follows: 
SFRP1 (rabbit polyclonal anti-human; Clone: sc-13939, San-
ta Cruz Biotechnology, Santa Cruz, CA, USA, dilution 1:200), 
beta-catenin (mouse monoclonal anti-human beta-catenin 
antibody; Dako Corporation, Carpinteria, CA, USA, dilution 
1:200), TCF1 (mouse monoclonal anti-human TCF1; Clone 
A-79, dilution 1:50), and LEF1 (Clone, REMB1; Santa Cruz Bio-
technology, Dallas, TX, USA, dilution 1:50) applied for 30 min 
at room temperature. Negative controls underwent the same 
staining procedure but the samples were not incubated with 
primary antibodies. Positive controls were the frontal cortex 
of the normal adult brain, human placenta, and normal hu-
man ovary tissues. Immunohistochemical analysis was eval-
uated by three independent observers in a blinded fashion, 
who had no knowledge on gene status, tumor stage, and 
demographic information. Cells in the hot spot, an area con-
taining the most characteristics of malignant tissue and most 
active proliferative rate, of each sample were analyzed. The 
staining intensity was scored by comparing immunoreactiv-
ity to normal tissue expression level and by using 10% and 
50% cut-offs as follows: 0/+: no reactivity or few focally weak-
ly positive cells (<10% tumor cells); ++: heterogeneous mod-
erate reactivity staining (10 to 50% tumor cells); +++: homo-
geneous intense reactivity (>50% tumor cells).
Quantitative stereological analysis of sFrP1 protein in 
brain tumor tissue
Quantitative stereological analysis of volume density (Vv) 
was performed by Nikon Alphaphot binocular light micro-
scope (Nikon, Vienna, Austria) using Weibel’s multipurpose 
test system with 42 points (M 42) at 400 × magnification 
(34). The area tested was 0.0837 mm2, and the total length 
of the lines was 1.008 mm. For each investigated group the 
orientation/pilot stereological measurement was carried 
out to define the number of fields to be tested. The volume 
density of SFRP1-positive cells was determined according 
to the point- counting method. Volume density was cal-
culated using the formula Vv = Pf/Pt, where Pf is the num-
ber of hits test points on SFRP1-positive cells and Pt is the 
number of all test points in the tested area.
statistical analysis
Sample size was determined based on tumor inci-
dence, financial considerations, and other studies of 
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similar size in the investigated field. Post-hoc power analy-
sis was performed regarding our primary aim. The normal-
ity of data was tested using the Shapiro-Wilk test. Pearson 
χ2 and Spearman’s correlation were used to test the rela-
tionships between SFRP1 hypermethylation and protein ex-
pression level, SFRP1 localizations, beta-catenin, TCF1 and 
LEF1, grades, and other clinical and demographic features. 
Significance level was set at P < 0.05. Statistical analysis was 
performed using Statistica, version 13.0 (Dell, Tulsa, OK, USA, 
licensed to the School of Medicine, University of Zagreb).
resuLts
SFRP1 promoter methylation
Epigenetic analysis found 32% (8/25) of methylated brain 
tumors. Malignant astrocytomas of different grades had 
very different methylation patterns of SFRP1 gene pro-
moter. All diffuse astrocytomas showed an unmethylated 
pattern (Figure 1A). Also, the majority of anaplastic astro-
cytomas (5/6 or 83.3%) showed an unmethylated pattern 
(Figure 1B). In the remaining one anaplastic astrocytoma 
sample, both gel bands were visible, the band demon-
strating the unmethylated promoter and the band dem-
onstrating the methylated promoter, but the band dem-
onstrating methylated promoter was stronger. There were 
7 of 13 glioblastoma samples with methylated SFRP1 pro-
moter (53.9%) (Figure 1C). All the methylated samples also 
had bands demonstrating unmethylated promoter, but 3 
of them had considerably stronger methylated bands. The 
remaining 46.2% (6/13) of glioblastomas had an unmeth-
ylated promoter without any trace of methylation (Table 
1). When we compared SFRP1 methylation status among 
tumor grades, a significant difference in methylation dis-
Figure 1. Methylation-specific polymerase-chain-reaction analysis for Secreted Frizzled Related Protein 1 (SFRP1) gene promoter 
in astrocytic brain tumors (A) grade ii (1Aii-6Aii); (B) grade iii (1Aiii-6Aiii); and (C) grade iV (1giV-13giV). the presence of a visible 
polymerase chain reaction product (band) in gel lanes marked u indicates the presence of unmethylated promotors; the product 
presence in lanes marked M indicates the presence of methylated promotors. Methylated human control (MC) was used as positive 
control for methylated reaction, human white blood cell dNA (WBC) was used as positive control for unmethylated reaction, and 
water was used as negative control.
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tribution was revealed (Pearson χ2 = 6.323; P = 0.042). Meth-
ylation of SFRP1 promoter appeared more frequently in 
glioblastoma than in other astrocytoma grades, which was 
confirmed by Spearman’s correlation analysis (Spearman’s 
rho 0.502; P = 0.011).
sFrP1 protein expression and its association to dNA 
methylation
Aberrant methylation alters gene expression. Therefore, we 
were interested in the expression levels of SFRP1 protein 
and its subcellular localization. The tissue expression lev-
els were determined by the semiquantitative method in 
the 3-stage signal strength and by quantitative stereologi-
cal analysis. The results obtained by two methods of signal 
quantification were strongly positively correlated (Spear-
man’s rho 0.518; P = 0.010).
In order to assess signal expression levels of SFRP1, the 
immunostains were compared to the expression levels 
of normal control tissues, which showed strong or mod-
erate SFRP1 expression levels. Of total astrocytoma sam-
ples, 45.8% (11/24) had weak or lack of SFRP1 protein ex-
pression, 25% (6/24) had moderate, and 29.2% (7/24) had 
strong expression. Subcellular distribution of SFRP1 protein 
was predominantly cytoplasmic, with only 20.8% (5/24) of 
samples showing simultaneous nuclear immunostain. Ex-
pression levels, when distributed to different grades, were 
tABLe 1. Promoter methylation status, expression levels, and localizations of secreted Frizzled related Protein 1 (sFrP1), beta-
catenin, lymphoid-enhancer factor 1 (LeF1), and t-cell factor 1 (tCF1) proteins in astrocytoma samples, and demographic and clinical 
data of astrocytoma patients
Worldhealth No. of
SFRP1 promoter 
methylation* Levels of expression
†
intracranial
organization grade patients status sFrP1 beta-catenin LeF1 tCF1 sex Age localization‡
AII (diffuse astrocytoma)  1 U 3 1 M 56 temporal R
 2 U 3 3 M 48 frontal R
 3 U 3 3 F 38 occipital R
 4 U 1 2 2 1 M 49 frontal R
 5 U 1 1 2 1 M 44 insular L
 6 U 1 2 1 2 M 32 temporal L
AIII (anaplastic astrocytoma)  1 U 2 2 F 55 frontal L
 2 U 3 3 M 58 frontal R
 3 U 3 3 M 46 frontal L
 4 U 1 2 2 1 F 34 frontoparietal parasagittal R
 5 U 1 2 3 3 M 24 frontal L
 6 M/U 2 2 2 1 M 51 frontal parasagittal L
G IV (glioblastoma)  1 U 1 1 3 2 M 68 parietal R
 2 U 1 3 2 1 M 56 frontal R
 3 M/u 1 2 1 F 54 temporooccipital R
 4 M/U 2 2 F 62 parietal R
 5 M/u 1 F 58 temporoparietal L
 6 U 1 1 3 2 F 77 temporal L
 7 U 1 1 3 3 M 60 temporal L
 8 M/U 1 3 3 1 F 56 parietal L
 9§ U 2 2 3 3 M 31 temporal L
10 U 3 3 1 1 F 71 frontal L
11 M/u 3 1 F 74 frontal R
12 M/U 1 2 3 3 F 56 temporal R
13II M/U 2 1 3 3 M 38 temporooccipital R
14II 2 1 3 3 M 54 frontal R
*M – methylated; u – unmethylated; bold – pronouncedly present, regular – present.
†1 – weak or lack of expression; 2 – moderate expression; 3 – strong expression.
‡r – right; L– left.
§Patients with isocitrate dehydrogenase 1 mutations.
iiPatients with ATRX Chromatin Remodeler mutations.
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not associated to any particular grade (Pearson χ2 = 2.218; 
P = 0.330). Samples with methylated SFRP1 showed signifi-
cantly lower SFRP1 protein expression than samples with 
unmethylated SFRP1 (Pearson χ2 = 8.874; P = 0.031) (Figure 
2B-D). Ratios of investigated analyses are shown in Table 2.
Activation of Wnt signaling in glioblastoma
We investigated if SFRP1 methylation and protein expres-
sion affected the activation/inactivation of Wnt signaling. 
Therefore, we investigated expression levels and subcellu-
lar localization of beta-catenin, whose up-regulation and 
transfer to the nucleus indicates Wnt activation. In 61.5% 
(16/26) of astrocytomas beta-catenin expression was up-
regulated (denoted as moderate and strong) as compared 
to weak expression observed in normal brain tissue, while 
in 57.7% (15/26) beta-catenin was found in the nucle-
us. In the glioblastoma group, this localization was even 
more pronounced (9/14; 64.3%). The majority of samples 
with unmethylated or predominantly unmethylated SFRP1 
promoter showed low beta-catenin expression levels. Sta-
tistical analysis confirmed this observation, showing that 
glioblastomas with unmethylated SFRP1 promoter had 
significantly less beta-catenin protein (Pearson χ2 = 4.550; 
P = 0.033). In glioblastomas with strongly methylated 
SFRP1, beta-catenin was up-regulated and transferred to 
the nucleus.
Up-regulation of transcriptional activators reveals the acti-
vation of Wnt signaling. Therefore, we tested the correlation 
between LEF1 and TCF1 expression levels and SFRP1 meth-
ylation pattern. Although 52.9% (9/17) and 41.2% (7/17) of 
total astrocytomas showed strong and moderate expres-
sion levels of LEF1 and TCF1, respectively, there was no cor-
relation to methylation profile or to SFRP1 expression: LEF1 
and methylation (Spearman’s rho = 0.079; P = 0.781), TCF1 
and methylation (Spearman’s rho = -0.084; P = 0.766), LEF1 
and SFRP1 expression (Spearman’s rho = 0.046; P = 0.867), 
TCF1 and SFRP1 expression (Spearman’s rho = 0.211; 
P = 0.433). However, strong LEF1 expression levels were 
significantly correlated with higher astrocytoma grades 
(Spearman’s rho 0.642, P = 0.006).
Figure 2. Characteristic immunohistochemical staining of secreted Frizzled related Protein 1 (sFrP1) expression in astrocytoma. 
(A) Negative control; (B) astrocytic brain tumor grade ii showing strong cytoplasmic staining; (C) astrocytic brain tumor grade iV 
(glioblastoma) showing strong cytoplasmic staining (both B and C with unmethylated promoters of SFRP1 gene); (D) astrocytic brain 
tumor grade iV (glioblastoma) with methylated promoter of SFRP1 gene showing lack of expression.
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Association to epidemiological characteristics
We also investigated the association of epidemiological 
characteristics of our astrocytoma samples to SFRP1 meth-
ylation status and expression levels of the proteins. Men 
had significantly more unmethylated tumors than wom-
en (Pearson χ2 = 4.588; P = 0.043). No significant association 
was observed between SFRP1 expression levels and sex. 
To investigate the differences between the patients’ age 
and methylation and expression patterns we divided our 
sample into two age groups: younger than 55 and older 
than 55. Age was not associated to methylation (Pearson 
χ2 = 1.186; P = 0.276), but 5 out of 8 methylated cases were 
in the >55 group. Age was also not associated to SFRP1 
expression. Both groups showed similar levels of SFRP1 ex-
pression.
The presence of IDH1 and ATRX mutations was also tested. 
Although IDH1 and ATRX mutation positivity was not sig-
nificantly associated to the methylation profile of SFRP1, all 
mutated cases had strong LEF1 and TCF1 expression lev-
els, and for TCF1 this association was marginally significant 
(Pearson χ2 = 4.950; P = 0.061). Beta-catenin expression was 
not associated to the mutation presence.
disCussioN
Our study showed that 32% of astrocytoma samples had 
hypermethylated promoter, and that the number of such 
samples increased from grade II to higher astrocytomas 
grades. Our hypothesis was affirmed and the results suggest 
that SFRP1 is involved in the progression of these tumors. 
As shown by methylation-specific PCR, all of diffuse astro-
cytomas had unmethylated SFRP1 promoter, while 16.7% of 
anaplastic and 53.9% of glioblastomas had methylated pro-
moter. Glioblastomas were significantly more methylated 
than lower astrocytoma grades. A given locus can have a 
different DNA methylation status because of extensive cell-
to-cell and tissue heterogeneity. In cancer DNA, both bands 
can be visible and have different intensities, since tumors 
consist of heterogeneous cells, some containing a methylat-
ed and some an unmethylated gene. Furthermore, the tran-
sition from unmethylated to methylated status of a gene in 
a specific group of tumor cells can be discrete.
Glioblastoma subtypes differ, among other things, in DNA 
methylation patterns of specific genes (6,38). There are 
genes which are present in the minority of one tumor type, 
but when they are present, their methylation status makes 
a considerable difference. Alterations of DNA methylation of 
cancer-causing genes can change the expression of such 
genes and result in transformation or progression of cancer 
cells (39). Furthermore, methylation status can also have pre-
dictive significance. For instance, patients with methylated 
O6-methylguanine-DNA-methyltransferase gene promoter 
benefit from alkylating agent chemotherapy.
Although in our total sample there was 45.8% of astrocy-
tomas with weak or lack of SFRP1 protein expression, 25% 
with moderate, and 29.2% with strong expression, the ob-
served expression values were not significantly assigned 
to any specific grade. However, we found that methylated 
cases expressed significantly less SFRP1 protein than unm-
ethylated. This result is in accordance with the role that has 
been assigned to SFRP1 in many cancers (40), including 
glioma: a missing SFRP1 cannot interact with Wnt pro-
teins, which enables Wnts to bind to frizzled receptors 
and activate the pathway.
tABLe 2. Secreted Frizzled Related Protein 1 (SFRP1) promoter methylation status, expression level of sFrP1, beta-catenin, lymphoid-
enhancer factor 1 (LeF1), and t-cell factor 1 (tCF1) proteins in astrocytoma samples
World health organization grade*
A ii (diffuse astrocytoma) A iii (anaplastic astrocytoma) g iV (glioblastoma)
u M/u M/u u M/u M/u u M/u M/u
Methylation status 
of SFRP1 promoter
6/6 5/6 1/6 6/13 3/13 3/13
1/13‡
Expression status† 1 2 3 1 2 3 1 2 3
SFRP1 3/6 3/6 2/6 2/6 2/6 6/12 4/12 2/12
Beta-catenin 2/6 2/6 2/6 4/6 2/6 8/14 3/14 3/14
LEF1 1/3 2/3 2/3 1/3 1/11 2/11 8/14
TCF1 2/3 1/3 2/2 1/3 4/11 2/11 5/11
*M – methylated; u – unmethylated; bold – pronouncedly present; regular – present.
†1 – weak or lack of expression; 2 – moderate expression; 3 – strong expression.
‡sample with same band intensities.
BASIC SCIENCE220 Croat Med J. 2018;59:213-23
www.cmj.hr
Several articles indicated that Wnt signaling was involved 
in glioblastoma invasion (15-17,41-44) and tumor cell mi-
gration (13,45). Furthermore, many authors have demon-
strated that SFRP1 suppresses tumor growth and inhibits 
Wnt signaling (46,47). Majchrzak-Celińska et al (32) showed 
that gliomas were characterized by aberrant promoter hy-
permethylation of many Wnt pathway antagonists, includ-
ing SFRP1. Their findings are similar but not identical to 
ours. They detected methylated tumors in all three grades, 
while we did not detect methylated grade II tumors and 
detected only one methylated grade III tumor. Also, they 
analyzed different types of glial tumors, while we focused 
only on astrocytic type. Nevertheless, they (32) also con-
cluded that SFRP1 methylation was more frequent in pa-
tients with tumor grades III and IV, which is consistent to 
our finding. Foltz et al (30) indicated that histone modifi-
cation was responsible for the epigenetic modulation of 
Wnt antagonist, showing that DKK1, SFRP1, and WIF1 had 
decreased expression in human glioblastoma.
Götze et al (1) found frequent promoter hypermethylation 
of several Wnt pathway inhibitor genes. Their results on 
SFRP1 across astrocytoma grades are similar to ours: grade 
III samples harbored 14.3% and grade IV 53.3% of methy-
lated promoters. They also reported lower SFRP1 expres-
sion in the methylated than in unmethylated samples, but 
on the mRNA level.
SFRPs are soluble proteins that modulate Wnt signaling 
(48,49). Although SFRPs family members were generally 
attributed with antagonistic mode of action (50,51), their 
action need not always be inhibitory (52,53). There is accu-
mulating evidence that specific SFRP members could also 
promote tumorigenesis, ie, act as agonists of Wnt signaling 
depending on the cellular and functional context (54). Our 
previous investigations on SFRP3 in astrocytomas (53) re-
vealed complex expression patterns distinct from the pres-
ent findings on SFRP1 expression. In the present study, we 
clearly demonstrated that this member of the SFRP family 
acted as a classical tumor suppressor in astrocytoma biol-
ogy. A recent comprehensive study on the context-specific 
roles of SFRPs (47) analyzed promoter methylation, gene 
expression, and survival data from 8000 tumors of 29 can-
cer types, finding that only SFRP1 consistently functioned 
as a tumor suppressor.
The Wnt pathway is activated through its main effector 
molecule, beta-catenin (23,41). We showed that glioblas-
toma samples with unmethylated SFRP1 promoter had 
significantly less beta-catenin protein. In the samples 
with strongly methylated SFRP1 promoter beta-catenin 
was up-regulated and transferred to the nucleus. Several 
studies including our previous research (55-58) showed 
that in glial tumors beta-catenin was up-regulated and ex-
pressed in the nucleus. The present study confirmed these 
findings but also presented a link between epigenetic si-
lencing of SFRP1 and beta-catenin expression. The follow-
ing scenario could explain our findings: since methylated 
samples failed to synthesize SFRP1 protein, there is no an-
tagonistic activity upon Wnt signaling and the oncogenic 
beta-catenin levels are rising. Similar results were obtained 
by Chang et al (59), who found a lower SFRP1 expression 
rate in glioblastoma than that in the normal brain and in-
versely correlated protein levels of SFRP1 and beta-catenin. 
They also showed that positive SFRP1 expression was asso-
ciated with longer overall survival rates. Kierulf-Vieira et al 
(60) showed that treatment with recombinant SFRP1 pro-
tein in primary glioma stem cell cultures down-regulated 
nuclear beta-catenin and decreased in vitro proliferation. 
Schiefer et al (31) studied the SFRP gene family in glioblas-
toma cell lines by using a different approach – inducing 
DNA demethylation by inhibiting DNA methyltransferases.
We found no significant association of transcription activa-
tors of Wnt signaling, LEF1 and TCF1, to methylation profile 
or to SFRP1 expression levels. This could be explained by 
the small sample size or by beta-catenin’s ability to switch 
co-transcriptional partners (61). Astrocytic tumors, espe-
cially glioblastoma, harbor great heterogeneity. The in-
vasive potential of glioblastoma tumor cells in the brain 
parenchyma is tremendous. There was, however, a corre-
lation between strong LEF1 expression and higher astro-
cytoma grades.
Several novel articles indicate that SFRP1 is a good candi-
date for a therapeutic target (43,62-64). Recently the anti-
proliferative activity of purified SFRP1 was demonstrated in 
two cancer cell lines (65), which is important for the devel-
opment of pharmaceutical interventions.
Our study is limited by small number of samples, which di-
minishes the statistical power and might have prevented 
us from detecting some possibly existing true associations, 
while the associations that reached significance might 
have been inflated. Post-hoc power analysis regarding our 
primary aim showed that comparison of SFRP1 methyla-
tion frequency between glioblastoma and other tumor 
types had 46.7% power. Therefore, our results should be 
interpreted with caution before they are independently 
reproduced. Further studies with a larger sample size are 
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needed to elucidate the precise mechanism by which 
SFRP1methylation affects glioma biology and the poten-
tial associations to prognosis.
Since biological and clinical behaviors of astrocytoma 
could only partially be explained by morphology, it is 
important to search for and define novel molecular bio-
markers. Our results indicate that SFRP1 is involved in the 
progression of astrocytic glial tumors, offering a potential 
methylation biomarker.
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